June 23, 2020 / 11:21 AM / 18 days ago

BRIEF-Seelos Announces Final Data From Phase I Pk/Pd Study Of Intranasal Racemic Ketamine

June 23 (Reuters) - Seelos Therapeutics Inc:

* SEELOS THERAPEUTICS ANNOUNCES FINAL DATA FROM PHASE I PK/PD STUDY OF INTRANASAL RACEMIC KETAMINE (SLS-002) AND CLINICAL DEVELOPMENT PLANS

* SEELOS THERAPEUTICS INC - SLS-002 WAS SAFE AND WELL TOLERATED ACROSS ALL DOSES

* SEELOS THERAPEUTICS - FDA FEEDBACK FROM TYPE C MEETING SUPPORTED DESIGN OF A 16 DAY STUDY FOR ACUTE SUICIDAL IDEATION AND BEHAVIOR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below